---
title: "Moleculin Biotech (MBRX) news: reverse split and delisting"
url: "https://aibio.space/companies/moleculin-biotech/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "MBRX reverse split, delisting, going concern and offering news: Moleculin Biotech gets Nasdaq staff determination on bid price, plans hearing request."
---

MBRX Moleculin Biotech, Inc. NASDAQ · United States

# Moleculin Biotech (MBRX) news MBRX reverse split, delisting and going concern news

Company Updates · 2026-09-29

## [Moleculin completes enrollment in Part A of its MIRACLE trial](https://aibio.space/news/moleculin-completes-enrollment-part-miracle-trial/)

The company reports 89 subjects enrolled, with two more in screening, and says it remains on track for a Part A readout in the first quarter of 2027.

## Latest Moleculin Biotech news

1. 2026-09-23 Financings [Moleculin sells 888,400 shares through at-the-market program in September](https://aibio.space/news/moleculin-sells-888-400-shares-through-market-program-september/) The sales raised $0.48 million, and anti-dilution terms cut the exercise price of the August 2026 Series I Warrants to $0.51.
2. 2026-09-18 Listings [Moleculin Biotech gets Nasdaq staff determination on bid price, plans hearing request](https://aibio.space/news/moleculin-biotech-gets-nasdaq-staff-determination-bid-price-plans/) Nasdaq staff says Moleculin is not eligible for a compliance period because it effected a 1-for-25 reverse stock split on December 1, 2025. The company plans to request a hearing, which stays any delisting action while it is pending.
3. 2026-08-21 Financings [Moleculin lifts ATM to $19.7M weeks after a $9.3M deal with 3x warrants](https://aibio.space/news/moleculin-lifts-atm-19-7m-weeks-after-9-3m-deal-3x-warrants/) Moleculin can now sell up to $19,700,000 under its at-the-market program, weeks after a July deal with warrants on 37,130,001 shares. The trial figures it cited are blinded and preliminary, drawn from 62 patients.
4. 2026-06-30 Company Updates [Moleculin calls first-45-patient MIRACLE results positive but gives no figures](https://aibio.space/news/moleculin-calls-first-45-patient-miracle-results-positive-but-gives-no/) The company says both Annamycin arms showed favorable efficacy trends against the control arm in relapsed or refractory AML, on a full intent-to-treat basis.
5. 2025-11-21 Listings [Moleculin Biotech gets Nasdaq delisting determination, plans hearing panel appeal](https://aibio.space/news/moleculin-biotech-gets-nasdaq-delisting-determination-plans-hearing/) Nasdaq staff issued a delisting determination against Moleculin Biotech's common stock for failing the $2.5 million stockholders' equity rule. The company said it will ask a hearing panel to stay any suspension, and its last annual report showed $4.3 million of cash and a going-concern warning.
6. 2025-08-29 Financings [Moleculin Biotech to raise up to $6.0 million through warrant inducement deal](https://aibio.space/news/moleculin-biotech-raise-up-6-0-million-through-warrant-inducement-deal/) Holders will exercise warrants for 16,216,216 shares at $0.37. They get new Series F warrants for 64,864,864 shares at $0.55, pending shareholder approval.
7. 2025-06-27 Listings [Moleculin Biotech gets Nasdaq bid price notice, has until December 24, 2025](https://aibio.space/news/moleculin-biotech-gets-nasdaq-bid-price-notice-has-until-december-24/) The stock closed below $1.00 for 30 straight business days. The company may consider a reverse stock split to regain compliance.

## Moleculin Biotech at a glance

- **Ticker**: MBRX

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $7.3 million

### Related companies

- [TG Therapeutics](https://aibio.space/companies/tg-therapeutics/) NASDAQ: TGTX
- [Theriva Biologics](https://aibio.space/companies/theriva-biologics/) AMEX: TOVX
- [EyePoint](https://aibio.space/companies/eyepoint/) NASDAQ: EYPT
- [Avenue Therapeutics](https://aibio.space/companies/avenue-therapeutics/) OTC: ATXI
- [Panbela Therapeutics](https://aibio.space/companies/panbela-therapeutics/) OTC: PBLA
- [NanoViricides](https://aibio.space/companies/nanoviricides/) AMEX: NNVC
- [Cullinan Therapeutics](https://aibio.space/companies/cullinan-therapeutics/) NASDAQ: CGEM
- [MabCure](https://aibio.space/companies/mabcure/) OTC: MBCI

### Also on NASDAQ

- [BlossomHill Therapeutics](https://aibio.space/companies/blossomhill-therapeutics/) BLSM
- [Nexentis Technologies](https://aibio.space/companies/nexentis-technologies/) NXTS
- [Compugen](https://aibio.space/companies/compugen/) CGEN
- [ORASURE TECHNOLOGIES INC](https://aibio.space/companies/orasure-technologies/) OSUR
- [Contineum Therapeutics](https://aibio.space/companies/contineum-therapeutics/) CTNM
- [Cogent Biosciences](https://aibio.space/companies/cogent-biosciences/) COGT

## Moleculin Biotech annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | [$0](https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/) | [$0](https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/) |
| Research and development | [$15.9 million](https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/) | [$17.7 million](https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/) |
| Net income (loss) | [-$33.6 million](https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/) | [-$26.0 million](https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/) |
| Cash from operations | [-$22.7 million](https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/) | [-$23.9 million](https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/) |
| Cash and equivalents | [$8.9 million](https://www.sec.gov/Archives/edgar/data/1659617/000143774926027688/) | [$4.3 million](https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $7.3 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Moleculin Biotech

Did Moleculin Biotech do a reverse stock split?

Our latest story on this, dated Sep 18, 2026: "Moleculin Biotech gets Nasdaq staff determination on bid price, plans hearing request". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/moleculin-biotech-gets-nasdaq-staff-determination-bid-price-plans/).

Was Moleculin Biotech delisted?

Our latest story on this, dated Sep 18, 2026: "Moleculin Biotech gets Nasdaq staff determination on bid price, plans hearing request". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/moleculin-biotech-gets-nasdaq-staff-determination-bid-price-plans/).

Has Moleculin Biotech issued a going-concern warning?

Our latest story on this, dated Nov 21, 2025: "Moleculin Biotech gets Nasdaq delisting determination, plans hearing panel appeal". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/moleculin-biotech-gets-nasdaq-delisting-determination-plans-hearing/).

Has Moleculin Biotech raised money recently?

Our latest story on this, dated Sep 23, 2026: "Moleculin sells 888,400 shares through at-the-market program in September". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/moleculin-sells-888-400-shares-through-market-program-september/).

What is the ticker symbol of Moleculin Biotech?

Moleculin Biotech, Inc. trades under the ticker MBRX on NASDAQ.

Where is Moleculin Biotech listed?

Moleculin Biotech, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:MOL; LSE:0K2H.

What is the SEC CIK of Moleculin Biotech?

The SEC Central Index Key (CIK) for Moleculin Biotech, Inc. is 1659617. Its filings are on SEC EDGAR.

How many shares does Moleculin Biotech have outstanding?

19,477,380 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-13.

Which country or territory is Moleculin Biotech listed under?

Our directory records Moleculin Biotech, Inc. under United States.

What does Moleculin Biotech do?

Our directory classifies Moleculin Biotech, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Moleculin Biotech?

The ISIN recorded for Moleculin Biotech, Inc. is US60855D5077.

Does aibio.space cover Moleculin Biotech?

aibio.space lists Moleculin Biotech, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Moleculin Biotech incorporated?

SEC records list its state or country of incorporation as DE.

What was Moleculin Biotech's revenue last year?

$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is Moleculin Biotech profitable?

Moleculin Biotech, Inc. reported a net loss of $33.6 million for the fiscal year ended Dec 31, 2025, and used $22.7 million of cash in operations, per its annual report to the SEC.

## Investor discussion: Moleculin Biotech

Members talk about Moleculin Biotech (MBRX). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Moleculin Biotech, newest first. Each line links the filing it comes from.

1. 2026-10-20 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774926032969/mbrx20261015d_8k.htm)
2. 2026-10-09 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774926032455/mbrx20261009_8k.htm)
3. 2026-09-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774926030757/mbrx20260914_8k.htm)
4. 2026-08-24 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774926028835/mbrx20260817_def14a.htm)
5. 2026-08-21 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774926028751/mbrx20260817_424b5.htm)
6. 2026-08-14 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774926028049/mbrx20260804_pre14a.htm)
7. 2026-07-29 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774926024774/mbrx20260716_s1.htm)
8. 2026-02-20 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774926004800/mbrx20260219_8k.htm)
9. 2026-01-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774926000695/mbrx20260106_8k.htm)
10. 2025-12-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774925038047/mbrx20251215_8k.htm)
11. 2025-12-10 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774925037414/mbrx20251210_8k.htm)
12. 2025-11-28 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774925036488/mbrx20251124_8k.htm)
13. 2025-11-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774925036006/mbrx20251121_8k.htm)
14. 2025-08-29 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774925027975/mbrx20250828_8k.htm)
15. 2025-08-18 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774925027241/mbrx20250818c_8k.htm)
16. 2025-07-11 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774925022604/mbrx20250629_424b5.htm)
17. 2025-07-08 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774925022352/mbrx20250630_def14a.htm)
18. 2025-06-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774925021445/mbrx20250627_8k.htm)
19. 2025-06-27 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774925021447/mbrx20250623_pre14a.htm)
20. 2025-06-23 Financings Reported a financing. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774925020979/mbrx20250618_424b4.htm)
21. 2025-06-02 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774925019188/mbrx20250529c_s1.htm)
22. 2025-05-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774925018358/mbrx20250523_8k.htm)
23. 2025-02-13 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774925003760/mbrx20250213c_8k.htm)
24. 2024-12-13 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1659617/000143774924037491/mbrx20241210_s1.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:MBRX on TradingView](https://www.tradingview.com/symbols/NASDAQ-MBRX/).

## SEC filings and registration

- **SEC name**: Moleculin Biotech, Inc.

- **CIK**: 1659617

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: MBRX (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: 5300 MEMORIAL DRIVE, HOUSTON, TX, 77007

- **Phone**: 713-300-5160

- **Shares outstanding**: 19,477,380 as of 2026-08-06 (10-Q filed 2026-08-13)

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1659617/000143774926032969/mbrx20261015d_8k.htm) filed 2026-10-20
- [8-K](https://www.sec.gov/Archives/edgar/data/1659617/000143774926032762/mbrx20261015_8k.htm) filed 2026-10-16
- [8-K](https://www.sec.gov/Archives/edgar/data/1659617/000143774926032455/mbrx20261009_8k.htm) filed 2026-10-09
- [8-K](https://www.sec.gov/Archives/edgar/data/1659617/000143774926031978/mbrx20260928c_8k.htm) filed 2026-10-05
- [8-K](https://www.sec.gov/Archives/edgar/data/1659617/000143774926031419/mbrx20260928_8k.htm) filed 2026-09-29
- [8-K](https://www.sec.gov/Archives/edgar/data/1659617/000143774926031280/mbrx20260925_8k.htm) filed 2026-09-28
- [8-K](https://www.sec.gov/Archives/edgar/data/1659617/000143774926031199/mbrx20260924_8k.htm) filed 2026-09-25
- [8-K](https://www.sec.gov/Archives/edgar/data/1659617/000143774926031005/mbrx20260922_8k.htm) filed 2026-09-23

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001659617), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Moleculin Biotech, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker MBRX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Moleculin Biotech, Inc.

- **Ticker**: MBRX

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: US60855D5077

- **Other listed symbols**: GETTEX:MOL; LSE:0K2H

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-MBRX/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/moleculin-biotech/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Moleculin Biotech (MBRX) news: reverse split and delisting", 2026-10-31, https://aibio.space/companies/moleculin-biotech/